



Q1 2023 CORPORATE UPDATE

TSXV: **VPT** | OTCQB: **VPTDF**

June 2023

FORWARD LOOKING STATEMENTS

Ventripoint Diagnostics Disclaimer The information in this presentation may include forward-looking statements related to our future growth, trends in our industry, our financial and or operational results, and our financial or operational performance. Such forward-looking statements are predictive in nature, and may be based on current expectations, forecasts or assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from the forward-looking statements themselves. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, or similar expressions, or may employ such future or conditional verbs as “may”, “will”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. For these statements, we claim the protection of the safe harbour for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. The risks and uncertainties referred to above include, but are not limited to: variability of operating results among periods; inability to retain or grow our business due to execution problems resulting from significant headcount reductions, plant closures and product transfer associated with major restructuring activities; the effects of price competition and other business and competitive factors generally affecting the EMS industry; the challenges of effectively managing our operations during uncertain economic conditions; our dependence on a limited number of customers; our dependence on industries affected by rapid technological change; the challenge of responding to lower-than-expected customer demand; our ability to successfully manage our international operations; and delays in the delivery and/or general availability of various components used in the manufacturing process. These and other risks and uncertainties and factors are discussed in the Company’s various public filings at www.sedar.com and www.sec.gov, including our Form 20-F and subsequent reports on Form 6-K filed with the Securities and Exchange Commission. Except as required by applicable law, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



MISSION: Improving the Lives of Patients

To improve the lives of patients by providing clinicians with the tools they need to deliver improved patient care, experiences, and outcomes. We aim to become the standard of care.

VISION: To elevate cardiac care

The technology was founded on a heartfelt desire to find a better way to provide care to children without relying on the highly restrictive MRI and still providing doctors with complete and full information that they need to monitor the heart state and make a confident diagnosis and treatment decisions.



Sales and Marketing Highlights



Building awareness and establishing leads

- Attended the 55th annual meeting of the German Society for Pediatric Cardiology and Congenital Defects (February)
- Attended the DGK (German Society of Cardiology) conference (April)
- Ventripoint sponsored the 56th Annual Meeting of the Association for European Pediatric and Congenital Cardiology (AEPC) (April)
- Attended the American Society of Echo “State of the Art Echocardiography” (February)
- Attended Echocardiography in the Nations Capital event organized by Mayo Clinic Rochester, MN. E (May)
- 1100+ leads identified from across Europe/UK (Germany, Spain, Switzerland, Poland, France, Austria, New Zealand, Netherlands, Finland, Sweden, and Greece)



Sales and Marketing Highlights



Clinical value delivered to our customers

- Increased efficiency in the patient care path
- Enhanced patient outcomes
- Enhanced patient experience



Recent P.O.s and upcoming sales

- 6 P.O.s issued and outstanding.
- 10+ evaluations/demos completed, and customers qualified





HAVE QUESTIONS?

**GET IN TOUCH WITH VENTRIPOINT
DIAGNOSTICS LTD.**

www.ventripoint.com

INVESTOR RELATIONS

Jonathan L. Robinson, CFA
Partner

Oak Hill Financial Inc.

Telephone: (416) 669-1001

E-mail : JRobinson@oakhillfinancial.ca